Severe	severe	O	O
rhabdomyolysis	rhabdomyolysis	O	S_disease
and	and	O	O
acute	acute	O	B_disease
renal	renal	O	B_disease
failure	failure	O	I_disease
secondary	secondary	O	O
to	to	O	O
concomitant	concomitant	O	O
use	use	O	O
of	of	O	O
simvastatin	simvastatin	S_chemical	O
,	,	O	O
amiodarone	amiodarone	S_chemical	O
,	,	O	O
and	and	O	O
atazanavir	atazanavir	S_chemical	O
.	.	O	O

OBJECTIVE	objective	O	O
:	:	O	O
To	to	O	O
report	report	O	O
a	a	O	O
case	case	O	O
of	of	O	O
a	a	O	O
severe	severe	O	O
interaction	interaction	O	O
between	between	O	O
simvastatin	simvastatin	S_chemical	O
,	,	O	O
amiodarone	amiodarone	S_chemical	O
,	,	O	O
and	and	O	O
atazanavir	atazanavir	S_chemical	O
resulting	resulting	O	O
in	in	O	O
rhabdomyolysis	rhabdomyolysis	O	S_disease
and	and	O	O
acute	acute	O	B_disease
renal	renal	O	B_disease
failure	failure	O	I_disease
.	.	O	O

BACKGROUND	background	O	O
:	:	O	O
A	a	O	O
72-year-old	72-year-old	O	O
white	white	O	O
man	man	O	O
with	with	O	O
underlying	underlying	O	O
human	human	O	O
immunodeficiency	immunodeficiency	O	O
virus	virus	O	O
,	,	O	O
atrial	atrial	O	B_disease
fibrillation	fibrillation	O	I_disease
,	,	O	O
coronary	coronary	O	B_disease
artery	artery	O	I_disease
disease	disease	O	I_disease
,	,	O	O
and	and	O	O
hyperlipidemia	hyperlipidemia	O	O
presented	presented	O	O
with	with	O	O
generalized	generalized	O	O
pain	pain	O	S_disease
,	,	O	O
fatigue	fatigue	O	S_disease
,	,	O	O
and	and	O	O
dark	dark	O	O
orange	orange	O	O
urine	urine	O	O
for	for	O	O
3	3	O	O
days	days	O	O
.	.	O	O

The	the	O	O
patient	patient	O	O
was	was	O	O
taking	taking	O	O
80	80	O	O
mg	mg	O	O
simvastatin	simvastatin	S_chemical	O
at	at	O	O
bedtime	bedtime	O	O
(	(	O	O
initiated	initiated	O	O
27	27	O	O
days	days	O	O
earlier	earlier	O	O
)	)	O	O
;	;	O	O
amiodarone	amiodarone	S_chemical	O
at	at	O	O
a	a	O	O
dose	dose	O	O
of	of	O	O
400	400	O	O
mg	mg	O	O
daily	daily	O	O
for	for	O	O
7	7	O	O
days	days	O	O
,	,	O	O
then	then	O	O
200	200	O	O
mg	mg	O	O
daily	daily	O	O
(	(	O	O
initiated	initiated	O	O
19	19	O	O
days	days	O	O
earlier	earlier	O	O
)	)	O	O
;	;	O	O
and	and	O	O
400	400	O	O
mg	mg	O	O
atazanavir	atazanavir	S_chemical	O
daily	daily	O	O
(	(	O	O
initiated	initiated	O	O
at	at	O	O
least	least	O	O
2	2	O	O
years	years	O	O
previously	previously	O	O
)	)	O	O
.	.	O	O

Laboratory	laboratory	O	O
evaluation	evaluation	O	O
revealed	revealed	O	O
66,680	66,680	O	O
U/L	u/l	O	O
creatine	creatine	B_chemical	O
kinase	kinase	I_chemical	O
,	,	O	O
93	93	O	O
mg/dL	mg/dl	O	O
blood	blood	B_chemical	O
urea	urea	B_chemical	O
nitrogen	nitrogen	I_chemical	O
,	,	O	O
4.6	4.6	O	O
mg/dL	mg/dl	O	O
creatinine	creatinine	S_chemical	O
,	,	O	O
1579	1579	O	O
U/L	u/l	O	O
aspartate	aspartate	S_chemical	O
aminotransferase	aminotransferase	O	O
,	,	O	O
and	and	O	O
738	738	O	O
U/L	u/l	O	O
alanine	alanine	S_chemical	O
aminotransferase	aminotransferase	O	O
.	.	O	O

Simvastatin	simvastatin	S_chemical	O
,	,	O	O
amiodarone	amiodarone	S_chemical	O
,	,	O	O
and	and	O	O
the	the	O	O
patient	patient	O	O
's	's	O	O
human	human	O	O
immunodeficiency	immunodeficiency	O	O
virus	virus	O	O
medications	medications	O	O
were	were	O	O
all	all	O	O
temporarily	temporarily	O	O
discontinued	discontinued	O	O
and	and	O	O
the	the	O	O
patient	patient	O	O
was	was	O	O
given	given	O	O
forced	forced	O	O
alkaline	alkaline	O	O
diuresis	diuresis	O	O
and	and	O	O
started	started	O	O
on	on	O	O
dialysis	dialysis	O	O
.	.	O	O

Nine	nine	O	O
days	days	O	O
later	later	O	O
the	the	O	O
patient	patient	O	O
's	's	O	O
creatine	creatine	B_chemical	O
kinase	kinase	I_chemical	O
had	had	O	O
dropped	dropped	O	O
to	to	O	O
1695	1695	O	O
U/L	u/l	O	O
and	and	O	O
creatinine	creatinine	S_chemical	O
was	was	O	O
3.3	3.3	O	O
mg/dL.	mg/dl.	O	O
The	the	O	O
patient	patient	O	O
was	was	O	O
discharged	discharged	O	O
and	and	O	O
continued	continued	O	O
outpatient	outpatient	O	O
dialysis	dialysis	O	O
for	for	O	O
1	1	O	O
month	month	O	O
until	until	O	O
his	his	O	O
renal	renal	O	O
function	function	O	O
recovered	recovered	O	O
.	.	O	O

DISCUSSION	discussion	O	O
:	:	O	O
The	the	O	O
risk	risk	O	O
of	of	O	O
rhabdomyolysis	rhabdomyolysis	O	S_disease
is	is	O	O
increased	increased	O	O
in	in	O	O
the	the	O	O
presence	presence	O	O
of	of	O	O
concomitant	concomitant	O	O
drugs	drugs	O	O
that	that	O	O
inhibit	inhibit	O	O
simvastatin	simvastatin	S_chemical	O
metabolism	metabolism	O	O
.	.	O	O

Simvastatin	simvastatin	S_chemical	O
is	is	O	O
metabolized	metabolized	O	O
by	by	O	O
CYP3A4	cyp3a4	O	O
.	.	O	O

Amiodarone	amiodarone	S_chemical	O
and	and	O	O
atazanavir	atazanavir	S_chemical	O
are	are	O	O
recognized	recognized	O	O
CYP3A4	cyp3a4	O	O
inhibitors	inhibitors	O	O
.	.	O	O

CONCLUSIONS	conclusions	O	O
:	:	O	O
Pharmacokinetic	pharmacokinetic	O	O
differences	differences	O	O
in	in	O	O
statins	statins	S_chemical	O
are	are	O	O
an	an	O	O
important	important	O	O
consideration	consideration	O	O
for	for	O	O
assessing	assessing	O	O
the	the	O	O
risk	risk	O	O
of	of	O	O
potential	potential	O	O
drug	drug	O	O
interactions	interactions	O	O
.	.	O	O

In	in	O	O
patients	patients	O	O
requiring	requiring	O	O
the	the	O	O
concurrent	concurrent	O	O
use	use	O	O
of	of	O	O
statins	statins	S_chemical	O
and	and	O	O
CYP3A4	cyp3a4	O	O
inhibitors	inhibitors	O	O
,	,	O	O
pravastatin	pravastatin	S_chemical	O
,	,	O	O
fluvastatin	fluvastatin	O	O
,	,	O	O
and	and	O	O
rosuvastatin	rosuvastatin	O	O
carry	carry	O	O
the	the	O	O
lowest	lowest	O	O
risk	risk	O	O
of	of	O	O
drug	drug	O	O
interactions	interactions	O	O
;	;	O	O
atorvastatin	atorvastatin	O	O
carries	carries	O	O
moderate	moderate	O	O
risk	risk	O	O
,	,	O	O
whereas	whereas	O	O
simvastatin	simvastatin	S_chemical	O
and	and	O	O
lovastatin	lovastatin	S_chemical	O
have	have	O	O
the	the	O	O
highest	highest	O	O
risk	risk	O	O
and	and	O	O
should	should	O	O
be	be	O	O
avoided	avoided	O	O
in	in	O	O
patients	patients	O	O
taking	taking	O	O
concomitant	concomitant	O	O
CYP3A4	cyp3a4	O	O
inhibitors	inhibitors	O	O
.	.	O	O

